Brought to you by 
HMR withdraws from deal for Alliance's LiquiVent
13 Jul 1999
Executive Summary
HMR will develop and market Alliance's LiquiVent (perflubron), currently in Phase III trials for treatment of acute respiratory failure, in exchange for exclusive manufacturing and worldwide marketing rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
HMR withdraws from deal for Alliance's LiquiVent
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice